EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

A Multicenter, Randomized, Clinical Trial Assessing the Effect of rTG-Omega 3 Supplementation on Meibomian Gland Dysfunction Patients after Cataract Surgery rTG-Omega 3 for Meibomian Gland Dysfunction

Suji Hong, Minji Woo, Youngsub Eom, Hong Kyun Kim, Kyung Chul Yoon, Kyung Sun Na, Kyung Jin Cho, Hyung Keun Lee, Jong Suk Song

Journal of Ocular Pharmacology and Therapeutics · 2025

DOI: 10.1089/jop.2024.0160 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2025. Verfasst von Suji Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Korea University Guro Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Meibomian Gland Dysfunction, Cataract Extraction, Fatty Acids, Omega-3, Meibomian Glands. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: To investigate the effectiveness of re-esterified triglyceride form of omega 3 (rTG-omega 3) on patients with meibomian gland dysfunction (MGD) after cataract surgery.

Methods

This multicenter, randomized, investigator-blinded, clinical study was conducted between June 2021 and March 2023 and enrolled 107 patients with MGD who had undergone cataract surgery within 3 months at seven sites across South Korea. Patients were randomly assigned to rTG-omega 3 group or a control group. We compared (1) tear film break-up time (TBUT) (s), (2) corneal fluorescein staining score [National Eye Institute/Industry (NEI) scale], (3) conjunctival fluorescein staining score (NEI scale), (4) strip meniscometry (SM) tube score (mm), (5) MGD stage, (6) MG quality, (7) MG expressibility, (8) Standard Patient Evaluation of Eye Dryness (SPEED) score, and (9) Ocular Surface Disease Index (OSDI) scores at baseline and 6 and 12 weeks.

Results

TBUT, corneal fluorescein staining score, and SM tube score were significantly improved in the rTG-omega 3 group compared with control group ( P = 0.005, P = 0.003, and P = 0.0049, respectively). Subjective questionnaire responses were also improved significantly (SPEED score, P = 0.022; OSDI score, P = 0.0011). MGD parameters were not significantly different. However, during subanalysis, significant improvements in MG quality and expressibility were observed in the MGD stage 4 group with rTG-omega 3 supplementation ( P = 0.0177 and P = 0.0205, respectively). Discussion: rTG-omega 3 supplementation facilitated improvements in both objective and subjective parameters. In particular, MG quality and expressibility were significantly improved in the severe MGD group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meibomian Gland DysfunctionCataract ExtractionFatty Acids, Omega-3Meibomian GlandsHumansMaleFemaleAgedMiddle AgedRepublic of KoreaDietary SupplementsTearsDry Eye Syndromes

Stichwörter der Autor:innen

dry eye diseasemeibomian gland dysfunctionrTG-omega 3

Substanzen

Fatty Acids, Omega-3

Autor:innen und Institutionen

  • Department of Ophthalmology, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Department of Ophthalmology, Seoul Shinsegae Eye Center, Eui Jung Bu, Gyeonggi-do, South Korea.
  • Department of Ophthalmology, Korea University Ansan Hospital, Gyeonggi-do, Republic of Korea.
  • Department of Ophthalmology, Kyungpook National University School of Medicine, Daegu, South Korea.
  • Department of Ophthalmology, Chonnam National University Medical School, Gwangju, South Korea.
  • Department of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

Zitieren

APA

Hong, S., Woo, M., Eom, Y., Kim, H. K., Yoon, K. C., Na, K. S., Cho, K. J., Lee, H. K., & Song, J. S. (2025). A Multicenter, Randomized, Clinical Trial Assessing the Effect of rTG-Omega 3 Supplementation on Meibomian Gland Dysfunction Patients after Cataract Surgery rTG-Omega 3 for Meibomian Gland Dysfunction. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2024.0160

Vancouver

Hong S, Woo M, Eom Y, Kim HK, Yoon KC, Na KS, et al. A Multicenter, Randomized, Clinical Trial Assessing the Effect of rTG-Omega 3 Supplementation on Meibomian Gland Dysfunction Patients after Cataract Surgery rTG-Omega 3 for Meibomian Gland Dysfunction. Journal of Ocular Pharmacology and Therapeutics. 2025. doi:10.1089/jop.2024.0160

BibTeX
@article{Hong2025,
  author = {Hong, Suji and Woo, Minji and Eom, Youngsub and Kim, Hong Kyun and Yoon, Kyung Chul and Na, Kyung Sun and Cho, Kyung Jin and Lee, Hyung Keun and Song, Jong Suk},
  title = {A Multicenter, Randomized, Clinical Trial Assessing the Effect of rTG-Omega 3 Supplementation on Meibomian Gland Dysfunction Patients after Cataract Surgery rTG-Omega 3 for Meibomian Gland Dysfunction},
  journal = {Journal of Ocular Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.1089/jop.2024.0160}
}
Kostenlos starten →